🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We are delighted to announce the successful launch of Pheon Therapeutics with a $68M #SeriesA to advance novel Antibody-Drug Conjugates for a wide range of hard-to-treat #cancers. Read more: bit.ly/3y0vzRf #pheontx #ADCs #solidtumors #biotech

@Pheon_tx will develop and commercialize an antibody using @Biocytogen's proprietary #RenMice platform to develop a best-in-class ADC as part of an exclusive licensing agreement. Read more here: bit.ly/44x1ab6

@Pheon_tx proudly welcomes Cyrus Mozayeni as its new CEO. With 20+ years of biotech expertise, Cyrus will lead the Company in the next stage of Company growth as we advance our #ADC program targeting hard-to-treat cancers into the clinic. Read more: bit.ly/3O8PDYF

Welcome to Jeff Albers on his appointment as Chairman of the @Pheon_tx Board of Directors. #ADCs #oncology #CompanyGrowth #clinicaldevelopment

Pheon Therapeutics is pleased to announce the appointment of #oncology expert Arvin Yang, MD, PhD as its new CMO. As a seasoned CMO with over a decade of experience in advancing oncology therapies, he joins us to advance #ADCs for treatment of solid tumors. bit.ly/45qaxJE

@Pheon_tx is set to be in San Francisco next week, 8-11 January, for the 42nd Annual J.P. Morgan Healthcare Conference. Get in touch if you would like to meet with our CEO, Cyrus Mozayeni. #JPM2024 #PheonTherapeutics #Oncology #Innovation #ADCs

📣Pheon Therapeutics announces the closing of a $120m Series B financing to fund development of its differentiated #ADC pipeline!